Semin Arthritis Rheu:风湿性多肌痛的合并症

2020-06-23 xiangting MedSci原创

在诊断前后,PMR患者的合并症负担都很高。

这项研究旨在确定风湿性多肌痛(PMR)患者诊断前后的合并症负担,其中包括糖皮质激素(GC)相关性不良反应。

提取临床实践研究数据链1990-2016年间40岁以上患者的匿名电子病历。根据年龄、性别和普通医疗登记将PMR患者与3-5名对照进行匹配。估算了一系列合并症的患病率、累积概率和可能性。对各种协变量进行调整后,分别使用条件性logistic回归和Cox比例风险回归计算比值比(ORs)和危险比(HRs)。

将31,984例PMR患者与149,436例对照进行了匹配。PMR与血管疾病(校正后HR 1.23[95%置信区间(CI)1.19,1.28])以及呼吸系统(HR 1.25[1.18,1.32])、肾脏(HR 1.34[1.30,1.39])和自身免疫性疾病(HR 4.68[4.35,5.03])相关。与之相反,在PMR诊断前,癌症(调整后OR [OR] 0.89 [0.86,0.93])和神经系统疾病(OR 0.36[0.33,0.40])的风险显著降低。PMR患者出现与使用糖皮质激素(GC)相关合并症的风险升高。

在诊断前后,PMR患者的合并症负担都很高。尽管需要进一步的工作来充分理解这些关联,但临床医生应意识到该类患者中合并症的患病率很高,以及糖皮质激素治疗可能对合并症有影响。

原始出处:

Richard Partington. Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study. Semin Arthritis Rheu. August 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825884, encodeId=fe0d182588438, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Feb 07 06:38:49 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903184, encodeId=a9fa90318459, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/e6f4c8652cb247beac163a54731e26c3/b6db1181a1404437a022ecd100bad08f.jpg, createdBy=c0791576372, createdName=zhoujin4150, createdTime=Sun Nov 29 00:49:23 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972736, encodeId=dbe319e273604, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 26 01:38:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357535, encodeId=20bb135e5350c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 25 02:38:49 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825884, encodeId=fe0d182588438, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Feb 07 06:38:49 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903184, encodeId=a9fa90318459, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/e6f4c8652cb247beac163a54731e26c3/b6db1181a1404437a022ecd100bad08f.jpg, createdBy=c0791576372, createdName=zhoujin4150, createdTime=Sun Nov 29 00:49:23 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972736, encodeId=dbe319e273604, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 26 01:38:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357535, encodeId=20bb135e5350c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 25 02:38:49 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-11-29 zhoujin4150

    好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1825884, encodeId=fe0d182588438, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Feb 07 06:38:49 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903184, encodeId=a9fa90318459, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/e6f4c8652cb247beac163a54731e26c3/b6db1181a1404437a022ecd100bad08f.jpg, createdBy=c0791576372, createdName=zhoujin4150, createdTime=Sun Nov 29 00:49:23 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972736, encodeId=dbe319e273604, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 26 01:38:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357535, encodeId=20bb135e5350c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 25 02:38:49 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1825884, encodeId=fe0d182588438, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sun Feb 07 06:38:49 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903184, encodeId=a9fa90318459, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201129/e6f4c8652cb247beac163a54731e26c3/b6db1181a1404437a022ecd100bad08f.jpg, createdBy=c0791576372, createdName=zhoujin4150, createdTime=Sun Nov 29 00:49:23 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972736, encodeId=dbe319e273604, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Nov 26 01:38:49 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357535, encodeId=20bb135e5350c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 25 02:38:49 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-25 zhaojie88

相关资讯

二甲双胍可减轻激素副作用!Lancet子刊研究

近期发表在Lancet子刊的一项2期临床研究表明,二甲双胍会让糖皮质激素“更完美”,可保留其抗炎作用,而消除其代谢方面的副作用。

糖皮质激素在感染相关急症,如何使用?

糖皮质激素是一类基本结构为类固醇(甾体),有抗过敏、抗炎、抗毒、抗休克、抑制免疫应答、抑制气道高反应性等作用的药物,临床可用于感染相关疾病等的治疗。

Lancet Diabetes Endo:二甲双胍可改善长期糖皮质激素治疗导致的不良事件

研究认为,二甲双胍可改善需采用糖皮质激素治疗的炎症性疾病部分代谢和临床结果,值得进一步研究

Semin Arthritis Rheu:类风湿性关节炎中与羟氯喹、甲氨蝶呤、生物制剂和糖皮质激素相关的糖尿病

在RA患者中,羟氯喹、甲氨蝶呤和TNFi与患糖尿病的风险降低相关,而糖皮质激素与糖尿病的风险升高相关。

Lancet:糖皮质激素在新冠肺炎中的应用,听听中国一线医生的观点

前几日,Lancet刊登了Clark Russell等撰写的一篇评论文章[1],文章认为,在非临床试验的情况下,激素不应该用于治疗2019-nCoV导致的肺损伤或休克。针对此文,柳叶刀近日刊登了中日医院曹彬教授作为通讯作者的一篇文章“On the use of corticosteroids for 2019-nCoV pneumonia”,从中国一线临床医生的角度,提出了不同的看法。全文链接

2020 AA/RCP/SE指南:肾上腺功能不全患者围术期糖皮质激素管理

2020年2月,麻醉医师协会(英国)(AA)联合英国皇家医师学会(RCP)、英国内分泌学会(SE)共同发布了肾上腺功能不全患者围术期糖皮质激素管理指南。主要目的是确保肾上腺功能不全患者在围手术期被确认并充分补充糖皮质激素。